At its May 30 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency endorsed the approval of several cancer therapies. The drug review panel recommended granting marketing authorization for Cejemly , intended for the first-line treatment of metastatic non–small cell lung cancer in combination with platinum-based chemotherapy.of cancer-related deaths in Europe, resulting in a significant number of fatalities.
In combination with erlotinib for first-line treatment of adults with unresectable advanced, metastatic, or recurrent nonsquamous NSCLC with EGFR activating mutations In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for the treatment of adults with platinum-resistant recurrent disease who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agentsas a 25-mg/mL concentrate for solution for infusion. Its active ingredient, bevacizumab, is a monoclonal antibody that binds to VEGF.